Expertise:
Immunotherapy
Targeted Drug Therapy
Speciality:
Oncology
Gender:
Female
Language:
English

Primary Location

Mayo Clinic Florida

4500 San Pablo Road, Jacksonville, FL 32224

Directions

Get to Know Dr. Yanyan Lou

Dr. Yanyan Lou has earned a reputation as an innovative medical oncologist, helping advance the treatment of lung cancer, mesothelioma and other thoracic diseases through novel target therapies, immunotherapies, clinical trials and the latest translational research.

Lou is currently a professor at the Mayo Clinic. She plays an active role in the thoracic oncology program. She serves as vice chair of research and the associate director of the Early Cancer Therapeutics Program.

As part of the acclaimed multidisciplinary treatment program at the Mayo Clinic, Lou works closely with specialists such as surgeons, pathologists, pulmonologists, radiation oncologists and radiologists to ensure a personalized treatment regimen for each patient.

She has done extensive research into the effectiveness of novel drugs such as the immunotherapy drug pembrolizumab, also known by the brand name Keytruda, which has been approved by the FDA for treating several cancers, including certain types of mesothelioma.

Specialties of Dr. Yanyan Lou

  • Immunotherapy
  • Targeted drug therapy
  • Chemotherapy
  • Lung cancer
  • Thoracic cancers
  • Pleural mesothelioma
  • Advanced solid tumors

Dr. Yanyan Lou’s Experience and Medical Education

  • Mayo Clinic
  • University of Texas MD Anderson Cancer Center (Fellowship)
  • National Cancer Institute (Fellowship)
  • University of Texas Southwestern Medical Center (Residency)
  • West China University of Medical Science (Ph.D.)
  • Henan Medical University, China (M.D.)

Awards and Certifications

  • Board certified in medical oncology and internal medicine
  • Paul Calabresi Career Development Award for Clinical Oncology, National Cancer Institute (2019)
  • Eveleigh Family Career Development Award, Mayo Clinic (2017)
  • Jay and Deanie Stein Career Development Award, Mayo Clinic (2016)
  • Young Investigator Award, Chinese American Hematologist Oncologist Network (2015)

Mesothelioma Clinical Trials Under Dr. Yanyan Lou

  • A phase I/II clinical study studying the safety and effectiveness of pembrolizumab in comparison to pembrolizumab in combination with anetumab ravtansine for patients with pleural mesothelioma.

Publications of Dr. Yanyan Lou

  • Saliba, A. et al. (2021, June 17). Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology.
  • Marin-Acevedo, J.A., Kimbrough, E.O. & Lou, L. (2021, March 19). Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology & Oncology.
  • Duma, N. et al. (2019, August 30). Influence of Sociodemographic Factors on Treatment Decisions in Non-Small Cell Lung Cancer. Clinical Lung Cancer.
  • Lou, Y. et al. (2019, May). Hypereosinophilia in a patient with metastatic non-small cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy.